0001543637-26-000005
SEC filingOngoing operating losses narrowed modestly to -$49K from -$63K through cost controls, but heightened cash burn and critical liquidity position heighten dependency on additional capital to sustain prototype development and avoid business cessation.
Nu-Med Plus, Inc. (NUMD) continued its pre-revenue development stage in FY2025, posting an operating loss of -$49K, a 22.7% improvement from -$63K in FY2024. This narrowing reflects reduced operating expenses of $48,955 versus $63,331 prior year, as detailed in management's discussion of results of operations. With no revenues, these costs represent essential spending on prototype development following completion of initial lab setup and design phases. The improvement demonstrates cost discipline amid constrained resources, allowing modest progress despite funding limitations.
Strategically, the company faces existential risks without new capital infusions. Management explicitly warns that failure to raise funds could prevent continuation of business and execution of the business plan. Prototype refinement and FDA testing will demand further phased investments, with losses anticipated to grow during merger evaluation and regulatory pursuits. This outlook aligns with the company's development-stage profile, where capital access determines survival and milestone achievement.